Search Results | Clinical Cancer Research | American Association for Cancer Research

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer

Rosemarie de Haan, Michel M. van den Heuvel, Judi van Diessen, Heike M.U. Peulen, Erik van Werkhoven, Adrianus J. de Langen, Ferry Lalezari, Dick Pluim, Manon Verwijs-Janssen, Conchita Vens, Jan H.M. Schellens, Neeltje Steeghs, Marcel Verheij, Baukelien van Triest

Clin Cancer Res (2021) 27 (5): 1256–1266.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-2551

Published: 01 March 2021

View article

Includes: Supplementary data

Journal Articles

BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer

Clin Cancer Res (2020) 26 (11): 2466–2476.

DOI: https://doi.org/10.1158/1078-0432.CCR-19-3579

Published: 01 June 2020

View article

Includes: Supplementary data

Journal Articles

A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir

Vincent A. de Weger, Frederik E. Stuurman, Stijn L.W. Koolen, Johannes J. Moes, Jeroen J.M.A. Hendrikx, Emilia Sawicki, Bas Thijssen, Marianne Keessen, Hilde Rosing, Marja Mergui-Roelvink, Alwin D.R. Huitema, Bastiaan Nuijen, Jos H. Beijnen, Jan H.M. Schellens, Serena Marchetti

Clin Cancer Res (2019) 25 (18): 5466–5474.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-2299

Published: 13 September 2019

View article

Journal Articles

Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

Daniel D. Von Hoff, Drew W. Rasco, Elisabeth I. Heath, Pamela N. Munster, Jan H.M. Schellens, Nicolas Isambert, Christophe Le Tourneau, Bert O'Neil, Ron H.J. Mathijssen, Jose A. Lopez-Martin, W. Jeff Edenfield, Miguel Martin, Patricia M. LoRusso, Gordon L. Bray, Jorge DiMartino, Aaron Nguyen, Kejian Liu, Eric Laille, Johanna C. Bendell

Clin Cancer Res (2018) 24 (17): 4072–4080.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-3716

Published: 04 September 2018

View article

Includes: Supplementary data

Journal Articles

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers

Clin Cancer Res (2018) 24 (9): 2050–2059.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-2260

Published: 30 April 2018

View article

Includes: Supplementary data

Journal Articles

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity

Clin Cancer Res (2017) 23 (18): 5406–5415.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-0812

Published: 14 September 2017

View article

Includes: Supplementary data

Journal Articles

Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer

Jill J.J. Geenen, Jan H.M. Schellens

Clin Cancer Res (2017) 23 (16): 4540–4544.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-0520

Published: 14 August 2017

View article

Journal Articles

Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients

Remy B. Verheijen, Sander Bins, Ron H.J. Mathijssen, Martijn P. Lolkema, Leni van Doorn, Jan H.M. Schellens, Jos H. Beijnen, Marlies H.G. Langenberg, Alwin D.R. Huitema, Neeltje Steeghs

Clin Cancer Res (2016) 22 (23): 5738–5746.

DOI: https://doi.org/10.1158/1078-0432.CCR-16-1255

Published: 30 November 2016

View article

Journal Articles

First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies

Pamela Munster, Rahul Aggarwal, David Hong, Jan H.M. Schellens, Ruud van der Noll, Jennifer Specht, Petronella O. Witteveen, Theresa L. Werner, E. Claire Dees, Emily Bergsland, Neeraj Agarwal, Joseph F. Kleha, Michael Durante, Laurel Adams, Deborah A. Smith, Thomas A. Lampkin, Shannon R. Morris, Razelle Kurzrock

Clin Cancer Res (2016) 22 (8): 1932–1939.

DOI: https://doi.org/10.1158/1078-0432.CCR-15-1665

Published: 14 April 2016

View article

Includes: Supplementary data

Journal Articles

Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors

Clin Cancer Res (2016) 22 (4): 858–867.

DOI: https://doi.org/10.1158/1078-0432.CCR-15-1506

Published: 14 February 2016

View article

Journal Articles

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors

Clin Cancer Res (2016) 22 (4): 877–885.

DOI: https://doi.org/10.1158/1078-0432.CCR-15-1683

Published: 14 February 2016

View article

Includes: Supplementary data

Journal Articles

A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers

Ulrik N. Lassen, Didier Meulendijks, Lilian L. Siu, Vaios Karanikas, Morten Mau-Sorensen, Jan H.M. Schellens, Derek J. Jonker, Aaron R. Hansen, Mary E. Simcox, Kathleen J. Schostack, Dean Bottino, Hua Zhong, Markus Roessler, Suzana M. Vega-Harring, Tiantom Jarutat, David Geho, Ka Wang, Mark DeMario, Glenwood D. Goss

Clin Cancer Res (2015) 21 (2): 258–266.

DOI: https://doi.org/10.1158/1078-0432.CCR-14-1334

Published: 14 January 2015

View article

Includes: Supplementary data

Journal Articles

Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study

Clin Cancer Res (2014) 20 (22): 5663–5671.

DOI: https://doi.org/10.1158/1078-0432.CCR-14-0719

Published: 13 November 2014

View article

Includes: Supplementary data

Journal Articles

Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations

Lisa Zimmer, Fabrice Barlesi, Maria Martinez-Garcia, Veronique Dieras, Jan H.M. Schellens, Jean-Philippe Spano, Mark R. Middleton, Emiliano Calvo, Luiz Paz-Ares, James Larkin, Simon Pacey, Miro Venturi, Françoise Kraeber-Bodéré, Jean J.L. Tessier, Wilfried Ernst Erich Eberhardt, Michel Paques, Ernesto Guarin, Valerie Meresse, Jean-Charles Soria

Clin Cancer Res (2014) 20 (16): 4251–4261.

DOI: https://doi.org/10.1158/1078-0432.CCR-14-0341

Published: 13 August 2014

View article

Includes: Supplementary data

Journal Articles

Abcc4 Together with Abcb1 and Abcg2 Form a Robust Cooperative Drug Efflux System That Restricts the Brain Entry of Camptothecin Analogues

Fan Lin, Serena Marchetti, Dick Pluim, Dilek Iusuf, Roberto Mazzanti, Jan H.M. Schellens, Jos H. Beijnen, Olaf van Tellingen

Clin Cancer Res (2013) 19 (8): 2084–2095.

DOI: https://doi.org/10.1158/1078-0432.CCR-12-3105

Published: 15 April 2013

View article

Journal Articles

Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

Suzanne Leijen, Mark R. Middleton, Patricia Tresca, Françoise Kraeber-Bodéré, Veronique Dieras, Max E. Scheulen, Avinash Gupta, Vanesa Lopez-Valverde, Zhi-Xin Xu, Ruediger Rueger, Jean J.L. Tessier, Eliezer Shochat, Steve Blotner, Valerie Meresse Naegelen, Jan H.M. Schellens, Wilfried Ernst Erich Eberhardt

Clin Cancer Res (2012) 18 (17): 4794–4805.

DOI: https://doi.org/10.1158/1078-0432.CCR-12-0868

Published: 30 August 2012

View article

Includes: Supplementary data

Journal Articles

The European Medicines Agency Review of Pazopanib for the Treatment of Advanced Renal Cell Carcinoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

Maria Nieto, Jeanett Borregaard, Jens Ersbøll, George J.A. ten Bosch, Barbara van Zwieten-Boot, Eric Abadie, Jan H.M. Schellens, Francesco Pignatti

Clin Cancer Res (2011) 17 (21): 6608–6614.

DOI: https://doi.org/10.1158/1078-0432.CCR-11-1734

Published: 31 October 2011

View article

Journal Articles

Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors

Stijn L.W. Koolen, Petronella O. Witteveen, Robert S. Jansen, Marlies H.G. Langenberg, Roelien H. Kronemeijer, Annemarie Nol, Ignacio Garcia-Ribas, Sophie Callies, Karim A. Benhadji, Christopher A. Slapak, Jos H. Beijnen, Emile E. Voest, Jan H.M. Schellens

Clin Cancer Res (2011) 17 (18): 6071–6082.

DOI: https://doi.org/10.1158/1078-0432.CCR-11-0353

Published: 14 September 2011

View article

Journal Articles

SNPs and Haplotypes in DPYD and Outcome of Capecitabine–Response

Maarten J. Deenen, Jan H.M. Schellens, Annemieke Cats

Clin Cancer Res (2011) 17 (17): 5835–5836.

DOI: https://doi.org/10.1158/1078-0432.CCR-11-1746

Published: 01 September 2011

View article

Journal Articles

Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer

Maarten J. Deenen, Jolien Tol, Artur M Burylo, Valerie D. Doodeman, Anthonius de Boer, Andrew Vincent, Henk-Jan Guchelaar, Paul H.M. Smits, Jos H. Beijnen, Cornelis J.A. Punt, Jan H.M. Schellens, Annemieke Cats

Clin Cancer Res (2011) 17 (10): 3455–3468.

DOI: https://doi.org/10.1158/1078-0432.CCR-10-2209

Published: 15 May 2011

View article

Includes: Supplementary data

NARROW

Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer

BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer

A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir

Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity

Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer

Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients

First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies

Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors

A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers

Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study

Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations

Abcc4 Together with Abcb1 and Abcg2 Form a Robust Cooperative Drug Efflux System That Restricts the Brain Entry of Camptothecin Analogues

Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

The European Medicines Agency Review of Pazopanib for the Treatment of Advanced Renal Cell Carcinoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors

SNPs and Haplotypes in DPYD and Outcome of Capecitabine–Response

Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only